Noticias

A deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved medicine with a murky financial outlook.

An indirect comparison highlights Attruby’s potential as the better TTR stabiliser over Pfizer’s tafamidis in frontline ATTR-CM.

Can a push into oncology and next-generation therapies make up for Pfizer's post-Covid letdown?

The market seemed underwhelmed by last week's earnings announcement from Pfizer Inc. ( NYSE:PFE ) despite the healthy...

At 6.7%, Pfizer's dividend yield is exceptionally high, but whether it's sustainable is debatable.

As federal policy chills domestic demand, some companies are increasingly leaning on sales from international markets.

Pfizer's acquired and recently launched products generated strong growth last quarter.

In early May 2026, Novavax reported first-quarter revenue of US$139.51 million versus US$666.66 million a year earlier, swinging from net income of US$518.65 million to a net loss of US$9.49 million and posting basic and diluted loss per share of US$0.06 from continuing operations. Despite the year-on-year drop in sales and profitability, Novavax’s quarterly results exceeded market expectations and were underpinned by new Matrix-M licensing activity, including an upfront US$30 million...

Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has already been a powerful 2026 run for the mRNA pioneer. The rally is outpacing fellow vaccine names Pfizer (NYSE:PFE), up 2% near $26.10, and Novavax (NASDAQ:NVAX), basically flat ... Moderna Stock Is Up 6% Today: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?

Pfizer (NYSE: PFE) and Eli Lilly (NYSE: LLY) recently reported quarterly results that read like two scripts from opposite ends of pharma. Lilly posted 55.55% revenue growth from a position of strength. Pfizer is still rebuilding from the COVID cliff. Their M&A playbooks tell the story. Blowout Quarter Meets a Methodical Rebuild Lilly’s Q1 2026 ... Pfizer vs Eli Lilly: Different Bets on Pharma M&A

Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.

Pfizer (NYSE:PFE) received FDA approval for VEPPANU (vepdegestrant), the first PROteolysis TArgeting Chimera, or PROTAC, therapy for certain patients with endocrine-resistant advanced breast cancer. Positive Phase 3 data for ELREXFIO in relapsed or refractory multiple myeloma were reported, supporting potential expanded use in this blood cancer setting. Settlements with generic manufacturers extended U.S. patent protection for VYNDAMAX to 2031, affecting a key cardiology franchise. For...

Pfizer is an innovative pharmaceutical giant that investors have given up on, which is an opportunity if you think long-term.

Pfizer Inc. (NYSE:PFE) is one of the best high volume stocks to invest in according to hedge funds. On May 5, Pfizer reported a strong start to 2026, achieving Q1 revenues of $14.5 billion, which represents a 2% operational increase compared to the prior-year period. This growth was driven by a 22% operational revenue surge […]

If you are trying to generate income in retirement, these three high-yield healthcare stocks could be the perfect fit for you.

BMO Capital Markets Managing Director, BioPharma Equity Research Evan Seigerman joins Julie Hyman on Market Catalyst to discuss the battle for GLP-1 dominance between Novo Nordisk (NVO) and Eli Lilly (LLY).

Eli Lilly has a lofty valuation thanks to its strong GLP-1 growth, but don't count out these two competitors.

Darzalex and new launches fuel J&J's 17.8% oncology sales growth in Q1 as the company targets $50B in cancer sales by 2030.

Novavax's shares rise 16% after Q1 earnings beat estimates as the company expands Matrix-M partnerships across oncology and infectious diseases.

Is Pfizer a yield trap? No way.

In early May 2026, Pfizer reported first-quarter revenue of US$14.45 billion and net income of US$2.69 billion, with earnings per share easing slightly year on year while the company reaffirmed full-year 2026 revenue guidance of US$59.5 billion to US$62.5 billion and filed an US$8.42 billion employee share offering shelf registration. At the same time, Pfizer advanced its oncology franchise with positive Phase 3 data for multiple myeloma drug ELREXFIO and secured the first-ever FDA approval...

Investors often move like lemmings in the short term, giving long-term investors an opportunity to buy great companies.

Pfizer’s first-quarter results gave investors a clearer view of how much work the drugmaker’s newer portfolio is doing as the company continues moving away from its pandemic-era sales base. In a report given to TheStreet, Pfizer said revenue rose from a year earlier, helped by recently launched and ...

Novavax (NASDAQ:NVAX) executives used the company’s first-quarter 2026 earnings call to highlight continued progress in reshaping the business around partner-driven revenue, a leaner operating model, and selective internal R&D designed to seed additional collaborations. Strategy centered on par

Pfizer (NYSE:PFE) chief executive Albert Bourla has signaled a possible shift in tone around US vaccine policy, praising President Donald Trump's latest nominee to lead the Centers for Disease Control and Prevention after a turbulent year for the agency. In a Bloomberg TV interview Tuesday, Bourla called Erica Schwartz a very credible scientist, pointing to what could be a more conventional choice for the country's top public health role. Schwartz, who holds both medical and law degrees and previously served as deputy surgeon general during the first Trump administration, is now being viewed as a figure who could help stabilize an agency that has become increasingly important for vaccine makers.

Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest source outside a paycheck. They settle in cash, clear immediately, and can be redeployed or spent without selling property or waiting on private placements. Pharma is one of the few sectors where mature franchises, regulatory ... 6 Pharma Dividend Stocks Yielding Up to 6.44% — and They’ve Survived Every Market Crash

Pfizer (PFE) is back in focus after reporting first quarter 2026 results that topped analyst expectations, reaffirmed its full year guidance, and paired those figures with fresh product, legal and regulatory updates. See our latest analysis for Pfizer. Despite the earnings beat and a series of product, legal and regulatory updates in oncology and rare disease, market reaction has been measured, with a year to date share price return of 5.04% and 1 year total shareholder return of 23.99%. This...